JOSTING, A., H. MULLER, P. BORCHMANN, JW. BAARS, B. METZNER, H. DOHNER, I. AURER, Lenka ŠMARDOVÁ, D. NIEDERWIESER, K. SCHÄFER-ECKART, N. SCHMITZ, A. SUREDA, J. GLOSSMAN, V. DIEHL, D. DE JONG, M.L. HANSMANN, J. RAEMAEKERS and A. ENGERT. Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma. Journal of clinical oncology. United States: American Society of Clinical Oncology, 2010, vol. 28, No 34, p. 5074-5080, 6 pp. ISSN 0732-183X. |
Other formats:
BibTeX
LaTeX
RIS
@article{906577, author = {Josting, A. and Muller, H. and Borchmann, P. and Baars, JW. and Metzner, B. and Dohner, H. and Aurer, I. and Šmardová, Lenka and Niederwieser, D. and SchäferandEckart, K. and Schmitz, N. and Sureda, A. and Glossman, J. and Diehl, V. and De Jong, D. and Hansmann, M.L. and Raemaekers, J. and Engert, A.}, article_location = {United States}, article_number = {34}, keywords = {Hodgkin lymphoma}, language = {eng}, issn = {0732-183X}, journal = {Journal of clinical oncology}, title = {Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma.}, volume = {28}, year = {2010} }
TY - JOUR ID - 906577 AU - Josting, A. - Muller, H. - Borchmann, P. - Baars, JW. - Metzner, B. - Dohner, H. - Aurer, I. - Šmardová, Lenka - Niederwieser, D. - Schäfer-Eckart, K. - Schmitz, N. - Sureda, A. - Glossman, J. - Diehl, V. - De Jong, D. - Hansmann, M.L. - Raemaekers, J. - Engert, A. PY - 2010 TI - Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma. JF - Journal of clinical oncology VL - 28 IS - 34 SP - 5074-5080 EP - 5074-5080 PB - American Society of Clinical Oncology SN - 0732183X KW - Hodgkin lymphoma N2 - High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients (pts) with relapsed Hodgkin's lymphoma (HL). The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy. PATIENTS:Pts with histologically confirmed, relapsed HL were treated with two cycles of DHAP. In the standard arm (A), pts received myeloablative therapy with BEAM followed by PBSCT. Pts in the experimental arm (B) also received sequential cyclophosphamide, methotrexate and etoposide in high-doses before BEAM. RESULTS:Mortality was similar in both arms (20% and 18%). With a median observation time of 42 mo., there was no significant difference in terms of FFTF (P = .56) and OS (P = .82) between arms. CONCLUSION:Compared with conventional HDCT, additional SHDCT is associated with more adverse effects and does not improve the prognosis of pts with relapsed HL. ER -
JOSTING, A., H. MULLER, P. BORCHMANN, JW. BAARS, B. METZNER, H. DOHNER, I. AURER, Lenka ŠMARDOVÁ, D. NIEDERWIESER, K. SCHÄFER-ECKART, N. SCHMITZ, A. SUREDA, J. GLOSSMAN, V. DIEHL, D. DE JONG, M.L. HANSMANN, J. RAEMAEKERS and A. ENGERT. Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma. \textit{Journal of clinical oncology}. United States: American Society of Clinical Oncology, 2010, vol.~28, No~34, p.~5074-5080, 6 pp. ISSN~0732-183X.
|